Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

The News: A blood plasma replacement therapy from Spanish company Grifols SA (Barcelona) reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo, Labiotech.eu reports. The… Read more »

October wraps up healthcare IPOs with another strong week as 2018 biotech explosion still on record pace.

The News: The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development…. Read more »

Stodgy Johns Hopkins wants FDA to clear psilocybin mushrooms for depression. Here’s what you need to know (or recall) about the differences between magic shrooms and, say, LSD.

The News: Researchers from Johns Hopkins University (Baltimore) have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic… Read more »

Atrial fibrillation increases risk of dementia by 40%, Swedish study shows. Bring on those blood thinners, say researchers.

The News: New evidence suggests that atrial fibrillation, in which the heart has an irregular beat, is linked to an increased risk of dementia. An irregular heartbeat speeds up the… Read more »

Physician burnout taking center stage; what patients should know as burnout percentage soars.

The News: Nearly half of medical residents report burnout during their second year of residency, and 1 in 7 report regretting their career choice, according to a prospective study published online last… Read more »

Healthcare stocks bounce back Friday after really messy week, but still licking their wounds from recent global selloff.

After having their worst week in recent memory, with the NASDAQ HealthCare Index (IXHC) now down 8.6% since just Sept. 28, some healthcare stocks nonetheless blossomed with stupendous upswings. But… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

UK-based Arecor targets vast artificial pancreas market with fast insulin and stable glucagon. Wait; artificial what?

The News: UK biotech Arecor Ltd. (Cambridge) has raised $7.8 million (€6.7M) to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The… Read more »